Amylyx Pharmaceuticals Financials
| AMLX Etf | USD 2.03 0.03 1.50% |
Operating Margin 0.0178 | PE Ratio 2.9 | Profit Margin 0.1294 | Short Ratio 2.43 | EPS Estimate Current Year (1.60) |
Amylyx |
The data published in Amylyx Pharmaceuticals' official financial statements usually reflect Amylyx Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Amylyx Pharmaceuticals. For example, before you start analyzing numbers published by Amylyx accountants, it's critical to develop an understanding of what Amylyx Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Amylyx Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amylyx Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Amylyx Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amylyx Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Amylyx Pharmaceuticals' management manipulating its earnings.
Amylyx Pharmaceuticals Etf Summary
Amylyx Pharmaceuticals competes with Terns Pharmaceuticals, Acumen Pharmaceuticals, Inozyme PharmaInc, X4 Pharmaceuticals, and Day One. Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| ISIN | US0321085088 |
| CUSIP | 03237H101 |
| Region | Others |
| Investment Issuer | Others |
| Location | Massachusetts; U.S.A |
| Business Address | 43 Thorndike Street, |
| Etf Family | Pharmaceuticals |
| Fund Category | Others |
| Portfolio Concentration | Others |
| Benchmark | NYSE Composite |
| Website | amylyx.com |
| Phone | 617 682 0917 |
| Currency | USD - US Dollar |
You should never invest in Amylyx Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Amylyx Etf, because this is throwing your money away. Analyzing the key information contained in Amylyx Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Amylyx Pharmaceuticals Key Financial Ratios
Generally speaking, Amylyx Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Amylyx Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Amylyx Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Amylyx Pharmaceuticals reports annually and quarterly.Amylyx Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amylyx Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Amylyx Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amylyx Pharmaceuticals competition to find correlations between indicators driving Amylyx Pharmaceuticals's intrinsic value. More Info.Amylyx Pharmaceuticals is rated below average in price to book as compared to similar ETFs. It is rated below average in price to sales as compared to similar ETFs fabricating about 1.16 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Amylyx Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Amylyx Pharmaceuticals' Etf. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amylyx Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Amylyx Pharmaceuticals Systematic Risk
Amylyx Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amylyx Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Amylyx Pharmaceuticals correlated with the market. If Beta is less than 0 Amylyx Pharmaceuticals generally moves in the opposite direction as compared to the market. If Amylyx Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amylyx Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amylyx Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Amylyx Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Amylyx Pharmaceuticals Financials
What exactly are Amylyx Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Amylyx Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Amylyx Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Amylyx Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Amylyx Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Amylyx Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Amylyx Pharmaceuticals Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Amylyx Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Amylyx has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Amylyx Pharmaceuticals' financials are consistent with your investment objective using the following steps:- Review Amylyx Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Amylyx Pharmaceuticals' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Amylyx Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Amylyx Pharmaceuticals' stock is overvalued or undervalued.
Amylyx Pharmaceuticals May 6, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Amylyx Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amylyx Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amylyx Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Amylyx Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amylyx Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 103.39 | |||
| Value At Risk | (8.30) | |||
| Potential Upside | 7.95 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amylyx Pharmaceuticals. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Amylyx Etf please use our How to Invest in Amylyx Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
The market value of Amylyx Pharmaceuticals is measured differently than its book value, which is the value of Amylyx that is recorded on the company's balance sheet. Investors also form their own opinion of Amylyx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Amylyx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amylyx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Amylyx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amylyx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amylyx Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amylyx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.